id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0611-0056,FDA,FDA-2011-D-0611,Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009; Draft Guidance for Industry,Other,Guidance,2015-05-13T04:00:00Z,2015,5,2015-05-13T04:00:00Z,,2019-11-18T16:53:10Z,,0,0,0900006481addc66
FDA-2011-D-0611-0055,FDA,FDA-2011-D-0611,Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2015-05-13T04:00:00Z,2015,5,2015-05-13T04:00:00Z,2015-07-14T03:59:59Z,2015-07-14T01:30:24Z,2015-11528,0,0,0900006481addda4
FDA-2011-D-0611-0054,FDA,FDA-2011-D-0611,"Biosimilars: Questions and Answers Regarding Implementation of the
Biologics Price Competition and Innovation Act of 2009; Guidance for
Industry",Other,Guidance,2015-04-30T04:00:00Z,2015,4,2015-04-30T04:00:00Z,,2019-11-18T16:52:55Z,,0,0,0900006481ac56a1
FDA-2011-D-0611-0053,FDA,FDA-2011-D-0611,"Biosimilars: Questions and Answers Regarding Implementation of the
Biologics Price Competition and Innovation Act of 2009; Guidance for
Industry; Availability",Notice,Notice of Availability,2015-04-30T04:00:00Z,2015,4,2015-04-30T04:00:00Z,,2015-04-30T15:38:03Z,2015-10064,0,0,0900006481ac4d35